Patents by Inventor C. David Weaver

C. David Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Positive allosteric modulators of human melanocortin-4 receptor
    Patent number: 10294214
    Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: May 21, 2019
    Assignees: Vanderbilt University, King's College London, Glaxo Group Limited
    Inventors: Roger D. Cone, Michael J. Bishop, Eugene L. Stewart, Lawrence A. Wolfe, Jaques Pantel, Julien Sebag, C. David Weaver, Savannah Williams, Helen Cox, Iain Tough, Luis Diaz Gimenez, Subramanian Baskaran
  • POSITIVE ALLOSTERIC MODULATORS OF HUMAN MELANOCORTIN-4 RECEPTOR
    Publication number: 20170349571
    Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Inventors: Roger D. Cone, Michael J. Bishop, Eugene L. Stewart, Lawrence A. Wolfe, Jaques Pantel, Julien Sebag, C. David Weaver, Savannah Williams, Helen Cox, Ian Tough, Luis Diaz Gimenez, Subramanian Baskaran
  • Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
    Patent number: 9067894
    Abstract: The present invention provides small molecule activators of GIRK potassium channels and methods for use thereof.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 30, 2015
    Assignee: Vanderbilt University
    Inventor: C. David Weaver
  • Method of screening for compounds that modulate the activity of a molecular target
    Patent number: 6472151
    Abstract: The present invention provides a method for generating and isolating cell lines that functionally express molecular targets for drug discovery without utilizing information from the nucleic acid or amino acid sequence of the target protein. This procedure for the first time allows one to develop fast, high throughput screens for evaluation of test compounds that may modulate molecular targets whose specific nucleic acid or amino acid sequences are unavailable.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: October 29, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: C. David Weaver, Todd A. Verdoorn, Gordon W. Robinson